Frederic Simonin

Illkirch-graffenstaden, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

GPRASP1 deletion suppresses antinociceptive tolerance during chronic activation of delta opioid receptor in persistent pain.

GPRASP1 deletion suppresses antinociceptive tolerance during chronic activation of delta opioid receptor in persistent pain.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 16, 2025

GPRASP1 deletion in mice abrogates adverse side effects associated with chronic stimulation of Beta2-adrenoceptor.

GPRASP1 deletion in mice abrogates adverse side effects associated with chronic stimulation of Beta2-adrenoceptor.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 13, 2025

Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects.

Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects.

Journal: Journal of medicinal chemistry

Published: April 30, 2024

Characterization of anti-GASP motif antibodies that inhibit the interaction between GPRASP1 and G protein-coupled receptors.

Characterization of anti-GASP motif antibodies that inhibit the interaction between GPRASP1 and G protein-coupled receptors.

Journal: Analytical biochemistry

Published: September 13, 2022

Identification of an N-acylated-DArg-Leu-NH2 Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia.

Identification of an N-acylated-DArg-Leu-NH2 Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia.

Journal: Journal of medicinal chemistry

Published: May 19, 2021

Behavioral characterization, potential clinical relevance and mechanisms of latent pain sensitization.

Behavioral characterization, potential clinical relevance and mechanisms of latent pain sensitization.

Journal: Pharmacology & therapeutics

Published: April 16, 2021

Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Journal: RSC medicinal chemistry

Published: February 10, 2021

GPRASP/ARMCX Protein Family: Potential Involvement in Health and Diseases Revealed by their Novel Interacting Partners.

GPRASP/ARMCX Protein Family: Potential Involvement in Health and Diseases Revealed by their Novel Interacting Partners.

Journal: Current topics in medicinal chemistry

Published: August 11, 2020

Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia.

Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia.

Journal: ACS chemical neuroscience

Published: May 05, 2018

A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.

A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.

Journal: Pain

Published: May 01, 2018

The neuropeptide FF: a signal for M1 to M2 type switching in macrophages from the adipose tissue

The neuropeptide FF: a signal for M1 to M2 type switching in macrophages from the adipose tissue

Journal: Medecine sciences : M/S

Published: February 01, 2018

Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.

Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.

Journal: The Journal of clinical investigation

Published: August 01, 2017

Showing 1-12 of 31

Last Updated: 09/26/2026